Projektbeschreibung: |
Development of recombinant equine herpesvirus type-1 vectored gG vaccine against Rabies: Rabies virus (RV) is a neurotropic virus that causes a serious impact on animal and human health. It is the type-species of the Lyssavirus genus of the Rhabodviridae family in the Mononegavirales order. RV is an enveloped virus with a single-strand, negative sense RNA genome. The RV genome encodes five proteins: the nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G) and the viral RNA polymerase (L). Most rabies vaccines currently available in the market use attenuated or inactivated viruses as antigens. To overcome the problems related to the use of current live attenuated (e.g. residual pathogenicity) and inactivated (e.g. costly, frequent boosters required) vaccines, there is a need for novel vaccine strategies) |
---|---|
Projektleitung: | Univ.-Prof. Dr. Nikolaus Osterrieder |
Eintragende Einrichtung: | Institut für Virologie |
Projektlaufzeit: | 01.11.2011 bis 31.12.2013 |
Projekttyp: | Forschungsprojekt |
Mittelgeber: | Boehringer Ingelheim Vetmedica GmbH |